GleamWall
中文EN

SABS SAB Biotherapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1833214 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-40.9%
TTM net income YoY19.2%
TTM EPS YoY51.8%
Revenue 3-yr CAGR-72.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-3,244.9%
Net margin-2,579.0%
FCF margin-2,618.6%
EBITDA margin-2,895.0%

Returns

ROE-81.9%
ROA-53.2%
ROIC (approx.)-380.8%
Asset turnover0.02x

Leverage & solvency

Liabilities / assets41.2%
Debt / equity0.00x
Current ratio2.98x
Interest coverage-134.77x

Cash quality & payout

Operating cash flow / net income1.01x
Accruals ratio0.3%
Payout ratio—
Capex / revenue25.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$0$1.32M
R&D expense$34.35M$30.25M
SG&A expense$14.60M$13.98M
Operating income-$48.95M-$42.91M
Interest expense$240,664$318,401
Pretax income$13.27M—
Income tax$0$0
Net income$13.27M-$34.11M
EBITDA-$45.96M-$38.20M
EPS (basic)0.22-3.68
EPS (diluted)-0.79-3.68
Weighted avg. shares (diluted)61.34M9.26M
Balance sheet
Cash & equivalents$10.50M$8.90M
Short-term investments$86.09M$11.86M
Current assets$101.05M$23.79M
PP&E, net$13.31M$15.37M
Total assets$172.81M$44.20M
Current liabilities$10.68M$7.98M
Total liabilities$21.32M$18.23M
Shareholders' equity$151.50M$25.97M
Shares outstanding47.61M9.29M
Cash flow statement
Operating cash flow-$44.78M-$34.29M
Capital expenditure$933,156$337,262
Free cash flow-$45.71M-$34.63M
Investing cash flow-$121.71M-$11.96M
Financing cash flow$168.30M-$1.17M
Depreciation & amortization$2.99M$4.71M
Stock-based compensation$5.21M$2.94M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.